Michael Schenker - Dept Med Oncol, Univ Med & Pharm Craiova

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 205 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Five-year Outcomes with First-Line Nivolumab Plus Ipilimumab with 2 Cycles of Chemotherapy Versus 4 Cycles of Chemotherapy Alone in Patients with Metastatic Non-Small Cell Lung Cancer in the Randomized CheckMate 9LA Trial

Martin Reck,Tudor-Eliade Ciuleanu,Michael Schenker,Stephanie Bordenave,Manuel Cobo,Oscar Juan-Vidal,Niels Reinmuth,Eduardo Richardet,Enriqueta Felip,Juliana Menezes,Ying Cheng,Hideaki Mizutani,Bogdan Zurawski,Aurelia Alexandru,David P. Carbone,Shun Lu,Thomas John, Takekazu Aoyama, Diederik J. Grootendorst,Nan Hu, Laura J. Eccles, Luis G. Paz-Ares

EUROPEAN JOURNAL OF CANCER (2024)

Cited0Views0WOSBibtex

Five-year Outcomes with First-Line (1L) Nivolumab Plus Ipilimumab Plus Chemotherapy (N Plus I Plus C) Vs C in Patients (pts) with Metastatic NSCLC (mnsclc) in CheckMate 9LA

Martin Reck, Tudor-Eliade Ciuleanu,Michael Schenker,Stephanie Bordenave,Manuel Cobo, Oscar Juan-Vidal,Niels Reinmuth,Eduardo Richardet,Enriqueta Felip,Juliana Menezes,Ying Cheng,Hideaki Mizutani, David Paul Carbone,Shun Lu,Tom John, Takekazu Aoyama,Javed Mahmood,Nan Hu, Laura Eccles, Luis G. Paz-Ares

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

First-line Nivolumab (N) Plus Ipilimumab (I) Plus Chemotherapy (C) in Metastatic NSCLC (mnsclc): CheckMate 9LA 4-Year Clinical Update

Firas Baclin, David P. Carbone, Tudor-Eliade Ciuleanu,Michael Schenker,Manuel Cobo-Dols,Stephanie Bordenave, Oscar Juan-Vidal,Juliana Menezes,Niels Reinmuth,Eduardo Richardet,Ying Cheng,Hideaki Mizutani, Luis G. Paz-Ares,Shun Lu,Thomas John,Xiaoqing Zhang,Nan Hu, David Bantu, Vipul Baxi,Jaclyn Neely,Martin Reck

JOURNAL OF THORACIC ONCOLOGYno. 7 (2024): E51-E51

Cited0Views0Bibtex

A Preliminary Study Examining the Correlation Between EGFRI Treatment, Clinic Dermatoscopy Features, and Serum Levels of Anti-Alpha-Galactosyl IgE in Colorectal Cancer Patients

Cristina Maria Popa,Irina Florina Cherciu Harbiyeli,Ana Maria Ciurea,Irina Mihaela Cazacu,Simona Laura Ianosi,Michael Schenker,Adrian Saftoiu

GASTROENTEROLOGY INSIGHTSno. 2 (2024): 505-518

Cited0Views0Bibtex

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

JOURNAL OF CLINICAL ONCOLOGYno. 17 (2024)

Cited0Views0WOSBibtex

The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (Cscc)

M. Schenker,M. Klochikhin,D. Kirtbaya, L. Mother, M. Gschnell,C. Robert,N. Meyer,L. Flatz,S. Dalle, M. Beylot-Barry,T. Eigentler,R. Kloss Silverman,B. Gumuscu,J. Yuan,A. Bratland

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSno. 5 (2024): E81-E82

Cited0Views0Bibtex

Canakinumab Versus Placebo in Combination with First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results from the CANOPY-1 Trial

JOURNAL OF CLINICAL ONCOLOGYno. 2 (2024)

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn